<DOC>
	<DOCNO>NCT01713647</DOCNO>
	<brief_summary>To assess bioequivalence investigational TEST product market REFERENCE product measurement Plasma concentration Amlodipine , Losartan , Carboxylic acid losartan metabolite &amp; Hydrochlorothiazide plasma calculation bioequivalence parameter measurement follow ANOVA 90 % confidence interval statistical evaluation .</brief_summary>
	<brief_title>Bioequivalence Study Amlodipine / Losartan/ Hydrochlorothiazide PHARMALINE , Lebanon Under Fastion Conditions</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1 . Healthy subject . 2 . Ethnic Group : Arab &amp; Mediterranean 3 . Race : Mixed skin ( white &amp; black skin people ) . 4 . Age 1850 year 5 . Bodymass index 18.5 30.0 kg/m2 inclusive ( minimum 50 kg weight ) . 6 . Subject available whole study period give write informed consent 7 . Physical examination within normal range 8 . All laboratory screening result within normal range , assess clinically nonsignificant attend physician 9 . Vital sign within normal range . 10 . Kidney function test , Liver function test within normal range . 11 . Pre dose blood pressure 110/70 mmHg . 1 . Women childbearing potential , pregnant lactate woman . 2 . Ethnic Group ( Non Arab &amp; / Non Mediterranean ) 3 . History severe allergy allergic reaction study drug relate drug heparin 4 . Known history presence food allergy , surgical medical condition know interfere absorption , distribution , metabolism excretion drug 5 . History serious illness impact fate drug 6 . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological , liver kidney disease , unless judge clinically significant Principal Investigator , medical designate 7 . Clinically significant illness 4 week study Period I 8 . Serious mental disease , drug , alcohol , solvent caffeine abuse , smoke . 9 . Regular use medication 10 . Having take medication could affect investigated drug product : ) Regular consumption drug two week prior study initiation day , b ) consumption enzyme stimulate inhibit drug ( e.g . Barbiturates , Carbamazepine , Phenytoin , Amphetamine , benzodiazepine , cannabinoid , cocaine , opiates , phencyclidine , methadone ) one month study initiation 11 . Presence significant physical organ abnormality 12 . Donation 1 ) least 400 ml blood within 60 day , 2 ) 150 ml blood within 30 day , 3 ) 100 ml blood plasma platelet within 14 day study Period I 13 . Participation another bioequivalence study within 80 day prior start study Period I 14 . Following special diet ( e.g . vegetarian ) diet one month study initiation . 15 . Prior history hypersensitivity Amlodipine besylate , Losartan Potassium &amp; Hydrochlorothiazide . 16 . Consumption grapefruit grapefruit containing product within 7 day drug administration 17 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 18 . Exhausting physical exercise last 48 hour ( e.g . weight lift ) recent significant change dietary exercise habit . 19 . Any significant clinical abnormality include HBsAg , HCV , HIV 20 . Abnormal vital sign . 21 . Abnormal Kidney Liver function test . 22 . Vomiting , Diarrhea . 23 . Pre dose blood pressure le 110/70 mmHg 24 . Positive test elicit drug alcohol prior dosing period .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Bio-equivalence , crossover</keyword>
</DOC>